Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report 2017 - Novel Treatments Offer a Ray of Hope - Research and Markets

News provided by

Apr 26, 2017, 13:15 ET

DUBLIN, April 26, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research.

The report profiles 34 companies including many key and niche players such as:

Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Cardiorentis AG (Switzerland)
CVie Therapeutics Limited (Taiwan)
Cytokinetics, Inc. (USA)
Merck & Co. (USA)
Novartis AG (Switzerland)
Orion Corporation (Finland)
PhaseBio Pharmaceuticals, Inc. (USA)

Key Topics Covered:

1. INDUSTRY OVERVIEW

Market Outlook
Acute Heart Failure - An Overview of the Disease and Available Therapeutics
Diuretics and Vasodilators - The First Line Therapy for AHF
Select Key Diuretics for AHF Treatment by Dosage and Route of Administration
Comparison of Most Common Vasodilators Used in ADHF Treatment
Other Known Drugs for AHF - Lower Efficacy Thwarts Use
Comparison of Select Inotropic Therapies for Acute Heart Failure Treatment
Standard Approved AHF Therapeutics as per Agency Guidelines

2. MARKET DRIVERS, TRENDS & ISSUES

Conventional Therapies Leave Considerable Unmet Needs
Novel Treatments Offer a Ray of Hope
Key AHF Therapeutics in the Pipeline
Serelaxin Nears Trial Readout form RELAX-AHF-2
Ularitide - A Novel Drug in Development for AHF
Ularitide's Fate Hangs in Balance
Impact of Ularitide's Clinical Trial Outcomes
The Litany of Drug Failures Expands, Emphasis on Prevention Grows
Failure of TRV027 - A Disappointment
Other Promising Drugs under Development
CAP-1002 (Capricor Therapeutics, Inc.)
Istaroxime (CVie Therapeutics)
PB-1046 (PhaseBio Pharmaceuticals)
omecamtiv mecarbil (Cytokinetics & Amgen)
CXL-1427 (Bristol Myers Squibb)
Research Findings
Kidney Dysfunction - Predictor of Acute Heart failure
Genetic Influence on Heart Disease among African Americans
Higher Body Mass Index - A Key Risk Factor for AHF
Supplemental Oxygen Therapy May not be for All Cases of AHF
Macro Growth Drivers
Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics

3. TREATMENT OF ACUTE HEART FAILURE (AHF)

Acute Decompensated Heart Failure Treatment by Type and Action Mechanism
A Review of Drug Classes
ACE Inhibitors
Aldosterone Antagonists
Angiotensin II Receptor Blockers (ARBs)
ß-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Dosage of Diuretics Used in the Treatment of AHF
Inotropic Agents
Digoxin (Lanoxin)
Morphine
Vasodilators/Nitrates
Vasodilators Used in AHF Treatment: Type, Indications for Use and Side Effects
Drug Tolerance of Patients Based on Signs and Symptoms
Treatment on the Basis of Adverse Signs
Oliguria/Anuria (Cardiorenal Syndrome)
Drowsiness/Confusion
Hypotension (systolic BP<_0mmhg_ />
Persistent Pulmonary Edema
Lifestyle Changes

4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS

Types of AHF
Causes of AHF
Coronary Heart Disease
Cardiomyopathy
High BP
Damaged Heart Valves
Patho-Physiology of AHF
Signs and Symptoms
Low Output
Fluid Overload/Congestion
Left-Sided Failure
Right-Sided Failure
Biventricular Failure
Diagnosis
Classification of AHF
Left Side and Right Side
Systolic Dysfunction and Diastolic Dysfunction
Backward and Forward Failure
Low-Output Heart Failure and High-Output Heart Failure
Functional Classification
By NYHA
By American College of Cardiology/American Heart Association
Phases of Evaluation and Management of AHF Patients
Early/Initial Phase
In-Hospital Phase
Pre-Discharge Phase
Early Post-Discharge Phase

5. RECENT INDUSTRY ACTIVITY

Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic
Renova Acquires Stresscopin from Janssen
Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma
CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime
ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug
Trevena's TRV027 Fails to Meet Clinical Study Endpoints
NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras®
Cardiorentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF
FDA Grants Fast Track Designation to Cardiorentis' Ularitide
Bristol-Myers Squibb Completes Acquisition of Cardioxyl
Cardiorentis Completes Enrollment in Phase III Trial of Ularitide
Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide
Cardiorentis Enters into Collaboration with Roche
Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic
Cardiorentis Enters into 45 million Financing Agreement with HC Royalty
USPTO Grants Patent to Trevena's TRV027
FDA Declines Approval for Novartis' Serelaxin

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 35)

- The United States (18)
- Japan (2)
- Europe (10)

- Germany (2)
- The United Kingdom (2)
- Italy (1)
- Rest of Europe (5)

- Asia-Pacific (Excluding Japan) (5)

For more information about this report visit http://www.researchandmarkets.com/research/9nm929/acute_heart

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets